Abstract | BACKGROUND: METHODS: In 2 open-label clinical studies, patients who presented with a 5-FU/ capecitabine overdose or an early onset of severe toxicities were treated. Patients received uridine triacetate as soon as possible (most within the first 96 hours after 5-FU/ capecitabine). Outcomes included survival, resumption of chemotherapy, and safety. Their survival was compared with the survival of a historical cohort of overdose patients who received only supportive care. RESULTS: A total of 137 of 142 overdose patients (96%) treated with uridine triacetate survived and had a rapid reversal of severe acute cardiotoxicity and neurotoxicity; in addition, mucositis and leukopenia were prevented, or the patients recovered from them. In the historical cohort, 21 of 25 patients (84%) died. Among the 141 uridine triacetate-treated overdose patients with a diagnosis of cancer (the noncancer patients included 6 intentional or accidental pediatric overdoses), 53 resumed chemotherapy in < 30 days (median time after 5-FU, 19.6 days), and this indicated a rapid recovery from toxicity. Adverse reactions in patients receiving uridine triacetate included vomiting (8.1%), nausea (4.6%), and diarrhea (3.5%). CONCLUSIONS:
|
Authors | Wen Wee Ma, Muhammad Wasif Saif, Bassel F El-Rayes, Marwan G Fakih, Thomas H Cartwright, James A Posey, Thomas R King, Reid W von Borstel, Michael K Bamat |
Journal | Cancer
(Cancer)
Vol. 123
Issue 2
Pg. 345-356
(01 01 2017)
ISSN: 1097-0142 [Electronic] United States |
PMID | 27622829
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. |
Chemical References |
- Acetates
- Antimetabolites, Antineoplastic
- uridine triacetate
- Capecitabine
- Fluorouracil
- Uridine
|
Topics |
- Acetates
(therapeutic use)
- Antimetabolites, Antineoplastic
(adverse effects)
- Capecitabine
(adverse effects, therapeutic use)
- Drug Overdose
(drug therapy)
- Female
- Fluorouracil
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Uridine
(analogs & derivatives, therapeutic use)
|